News Releases

Search

Year

November 20, 2020

Cogent Biosciences to Participate in 3rd Annual Evercore ISI HealthCONx Virtual Conference

CAMBRIDGE, Mass. , Nov. 20, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will participate in a virtual

November 18, 2020

Cogent Biosciences Announces Final Results from PLX9486 Phase 1/2 Study in Advanced GIST Patients at CTOS 2020

Majority of patients treated with PLX9486 + sunitinib experienced clinical benefit with a median PFS of 12 months and 20% ORR, including a complete response, in a heavily pre-treated GIST population; 27% of patients remain on therapy out 27-34 months Combination showed no dose limiting toxicities

November 12, 2020

Cogent Biosciences to Present at Jefferies 2020 Virtual London Healthcare Conference

CAMBRIDGE, Mass. , Nov. 12, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will present a corporate

November 9, 2020

Cogent Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates

Andrew Robbins appointed President, CEO and Director Final results from PLX9486 + sunitinib Phase 1/2 study in GIST patients selected for oral presentation at Connective Tissue Oncology Society (CTOS) 2020 meeting Ended quarter with $129.4 million in cash, including proceeds from $104.4M Series

November 5, 2020

Cogent Biosciences to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

CAMBRIDGE, Mass. , Nov. 5, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will virtually present a

October 26, 2020

Cogent Biosciences Appoints Andrew Robbins as Chief Executive Officer

Seasoned executive with deep experience developing precision medicines for genetically defined diseases, most recently as COO of Array Biopharma CAMBRIDGE, Mass. , Oct. 26, 2020 /PRNewswire/ -- Cogent Biosciences , Inc. ("Cogent") (NASDAQ: COGT), a biotechnology company focused on developing

October 5, 2020

Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress

Cogent Biosciences is focused on the design of rational precision therapies to improve the lives of patients Company on track to advance CGT9486 into Systemic Mastocytosis patients in 1H21 Abstract selected for oral presentation at CTOS 2020 New data from the Phase 1/2 clinical trial of

August 31, 2020

Unum Therapeutics Transfers BOXR Cell-Based Therapy Technology to SOTIO

Transaction focused on the BOXR technology including lead program BOXR1030 Company fully focused on the development of small molecule precision kinase inhibitors to treat a range of genetically driven diseases Peter Harwin appointed as Board Chair CAMBRIDGE, Mass. , Aug.

August 11, 2020

Unum Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates

Completed acquisition of Kiq, including lead clinical-stage compound PLX9486, a potent and selective KIT D816V inhibitor Company positioned to advance best-in-class precision kinase inhibitors Advancing clinical trials in Systemic Mastocytosis and Gastrointestinal Stromal Tumors ('GIST')

July 6, 2020

Unum Therapeutics Inc. Announces Acquisition of Kiq LLC

Acquisition includes lead clinical-stage compound PLX9486, a potent and selective KIT D816V inhibitor Company positioned to advance best-in-class precision kinase inhibitors Proceeds of $104.4 million to be used to advance clinical testing in mastocytosis and GIST Conference call today at

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 15

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Unum disavows any obligation to update the information contained in such press releases after the date of their issuance.